A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1982-03

AUTHORS

Joseph C. Allegra, Thomas M. Woodcock, Stephen P. Richman, Kirby I. Bland, James L. Wittliff

ABSTRACT

Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity. More... »

PAGES

93-99

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01805721

DOI

http://dx.doi.org/10.1007/bf01805721

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046683463

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/6293630


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogens, Conjugated (USP)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allegra", 
        "givenName": "Joseph C.", 
        "id": "sg:person.01112043665.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112043665.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Woodcock", 
        "givenName": "Thomas M.", 
        "id": "sg:person.0661366665.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661366665.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richman", 
        "givenName": "Stephen P.", 
        "id": "sg:person.0613253465.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613253465.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Department of Surgery, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bland", 
        "givenName": "Kirby I.", 
        "id": "sg:person.01310402724.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310402724.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Department of Biochemistry, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wittliff", 
        "givenName": "James L.", 
        "id": "sg:person.055356332.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.055356332.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010993764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jso.2930090509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019634024"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022702791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197812142992403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024442011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810601)47:11<2552::aid-cncr2820471106>3.0.co;2-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026754802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2964(80)90206-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026853325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.75.2.980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028177544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197806012982203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029504560"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030818360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2964(80)90348-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043667003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-88-1-69", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073735321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074250300", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079517496", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080482003", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081608880", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1984.2.1.28", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081678326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081900341", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082313081", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082748058", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083118733", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1982-03", 
    "datePublishedReg": "1982-03-01", 
    "description": "Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf01805721", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "name": "A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer", 
    "pagination": "93-99", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "de61985d155bb859bffefbe4cf3db2870439306539c7891e7f640a32b06a63dd"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "6293630"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01805721"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046683463"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01805721", 
      "https://app.dimensions.ai/details/publication/pub.1046683463"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113664_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF01805721"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'


 

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      64 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01805721 schema:about N011ff5e31cba48c59887b585c065a443
2 N26c6cc44f30149a992d9df0c188c960a
3 N28c07f8407ce4908bf0b6de9733b8ec9
4 N3759f11e770040759d0ae9d50edff84a
5 N423827e8310c4077a2814cdfb23d53ab
6 N429dbba5359f4789b067e5a6a673fae3
7 N4efc8ec128da4a129fe4ebdf00fca59f
8 N586a25fa214e4daea0e866958e287732
9 N79f6d4ead4c0417e82ae038c785074fc
10 N95a35625a4b44e379b2d3419f0bc6bcf
11 Nc08655dc6aac4c5c9231b899f375524b
12 Nc90eb158747a425c902d0aa7520f01a0
13 Ncc1aff851b7e4c728d78c1d30d1f40c0
14 Nd8f6d458d1bc483ebefe99feffbb14ac
15 Ndd5d3568241b41c3ad70c6af9226bb85
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nbca168d95f104c19a84b7465d19c0b1f
19 schema:citation https://app.dimensions.ai/details/publication/pub.1074250300
20 https://app.dimensions.ai/details/publication/pub.1079517496
21 https://app.dimensions.ai/details/publication/pub.1080482003
22 https://app.dimensions.ai/details/publication/pub.1081608880
23 https://app.dimensions.ai/details/publication/pub.1081900341
24 https://app.dimensions.ai/details/publication/pub.1082313081
25 https://app.dimensions.ai/details/publication/pub.1082748058
26 https://app.dimensions.ai/details/publication/pub.1083118733
27 https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s
28 https://doi.org/10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p
29 https://doi.org/10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t
30 https://doi.org/10.1002/1097-0142(19810601)47:11<2552::aid-cncr2820471106>3.0.co;2-y
31 https://doi.org/10.1002/jso.2930090509
32 https://doi.org/10.1016/0014-2964(80)90206-6
33 https://doi.org/10.1016/0014-2964(80)90348-5
34 https://doi.org/10.1056/nejm197806012982203
35 https://doi.org/10.1056/nejm197812142992403
36 https://doi.org/10.1073/pnas.75.2.980
37 https://doi.org/10.1200/jco.1984.2.1.28
38 https://doi.org/10.7326/0003-4819-88-1-69
39 schema:datePublished 1982-03
40 schema:datePublishedReg 1982-03-01
41 schema:description Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree false
45 schema:isPartOf N99e58c1037e14ee392dbd6d82b7016d2
46 N9a6fc520d3f34ece9dcb992356752bf8
47 sg:journal.1092777
48 schema:name A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer
49 schema:pagination 93-99
50 schema:productId Nc734987daaca476ab3e216d6b80d47ae
51 Nceecc45f34ab45478b9f00a103ee4ede
52 Nd99a17f6c1934c819ea5144602860dbf
53 Nf4d579dafe08401791a23218840ac72d
54 Nfdb5fbc27d1c48e3aab437c8c0bfcaaf
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046683463
56 https://doi.org/10.1007/bf01805721
57 schema:sdDatePublished 2019-04-11T10:34
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N52624487c3a645caad548f746e3874fb
60 schema:url http://link.springer.com/10.1007/BF01805721
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N011ff5e31cba48c59887b585c065a443 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Fluorouracil
66 rdf:type schema:DefinedTerm
67 N26c6cc44f30149a992d9df0c188c960a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Breast Neoplasms
69 rdf:type schema:DefinedTerm
70 N277ec6e795774cd5a7e0fe7db5375db4 rdf:first sg:person.0613253465.61
71 rdf:rest Ndd2b5243a1544970bf7c5c784ada30a3
72 N28c07f8407ce4908bf0b6de9733b8ec9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Drug Therapy, Combination
74 rdf:type schema:DefinedTerm
75 N2c5fc5b2e2fd48da8e7ff235a48af8ab rdf:first sg:person.055356332.16
76 rdf:rest rdf:nil
77 N3759f11e770040759d0ae9d50edff84a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Receptors, Estrogen
79 rdf:type schema:DefinedTerm
80 N423827e8310c4077a2814cdfb23d53ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Tamoxifen
82 rdf:type schema:DefinedTerm
83 N429dbba5359f4789b067e5a6a673fae3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Adenocarcinoma
85 rdf:type schema:DefinedTerm
86 N4efc8ec128da4a129fe4ebdf00fca59f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Female
88 rdf:type schema:DefinedTerm
89 N52624487c3a645caad548f746e3874fb schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N586a25fa214e4daea0e866958e287732 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Antineoplastic Agents
93 rdf:type schema:DefinedTerm
94 N79f6d4ead4c0417e82ae038c785074fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Methotrexate
96 rdf:type schema:DefinedTerm
97 N95a35625a4b44e379b2d3419f0bc6bcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Humans
99 rdf:type schema:DefinedTerm
100 N99e58c1037e14ee392dbd6d82b7016d2 schema:volumeNumber 2
101 rdf:type schema:PublicationVolume
102 N9a6fc520d3f34ece9dcb992356752bf8 schema:issueNumber 1
103 rdf:type schema:PublicationIssue
104 Na4a8a21db86140ec95b9a7929a9a69b4 rdf:first sg:person.0661366665.98
105 rdf:rest N277ec6e795774cd5a7e0fe7db5375db4
106 Nbca168d95f104c19a84b7465d19c0b1f rdf:first sg:person.01112043665.26
107 rdf:rest Na4a8a21db86140ec95b9a7929a9a69b4
108 Nc08655dc6aac4c5c9231b899f375524b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Estrogens, Conjugated (USP)
110 rdf:type schema:DefinedTerm
111 Nc734987daaca476ab3e216d6b80d47ae schema:name readcube_id
112 schema:value de61985d155bb859bffefbe4cf3db2870439306539c7891e7f640a32b06a63dd
113 rdf:type schema:PropertyValue
114 Nc90eb158747a425c902d0aa7520f01a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Middle Aged
116 rdf:type schema:DefinedTerm
117 Ncc1aff851b7e4c728d78c1d30d1f40c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged
119 rdf:type schema:DefinedTerm
120 Nceecc45f34ab45478b9f00a103ee4ede schema:name nlm_unique_id
121 schema:value 8111104
122 rdf:type schema:PropertyValue
123 Nd8f6d458d1bc483ebefe99feffbb14ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Adult
125 rdf:type schema:DefinedTerm
126 Nd99a17f6c1934c819ea5144602860dbf schema:name dimensions_id
127 schema:value pub.1046683463
128 rdf:type schema:PropertyValue
129 Ndd2b5243a1544970bf7c5c784ada30a3 rdf:first sg:person.01310402724.66
130 rdf:rest N2c5fc5b2e2fd48da8e7ff235a48af8ab
131 Ndd5d3568241b41c3ad70c6af9226bb85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Drug Evaluation
133 rdf:type schema:DefinedTerm
134 Nf4d579dafe08401791a23218840ac72d schema:name pubmed_id
135 schema:value 6293630
136 rdf:type schema:PropertyValue
137 Nfdb5fbc27d1c48e3aab437c8c0bfcaaf schema:name doi
138 schema:value 10.1007/bf01805721
139 rdf:type schema:PropertyValue
140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
141 schema:name Medical and Health Sciences
142 rdf:type schema:DefinedTerm
143 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
144 schema:name Oncology and Carcinogenesis
145 rdf:type schema:DefinedTerm
146 sg:journal.1092777 schema:issn 0167-6806
147 1573-7217
148 schema:name Breast Cancer Research and Treatment
149 rdf:type schema:Periodical
150 sg:person.01112043665.26 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
151 schema:familyName Allegra
152 schema:givenName Joseph C.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112043665.26
154 rdf:type schema:Person
155 sg:person.01310402724.66 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
156 schema:familyName Bland
157 schema:givenName Kirby I.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310402724.66
159 rdf:type schema:Person
160 sg:person.055356332.16 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
161 schema:familyName Wittliff
162 schema:givenName James L.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.055356332.16
164 rdf:type schema:Person
165 sg:person.0613253465.61 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
166 schema:familyName Richman
167 schema:givenName Stephen P.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613253465.61
169 rdf:type schema:Person
170 sg:person.0661366665.98 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
171 schema:familyName Woodcock
172 schema:givenName Thomas M.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661366665.98
174 rdf:type schema:Person
175 https://app.dimensions.ai/details/publication/pub.1074250300 schema:CreativeWork
176 https://app.dimensions.ai/details/publication/pub.1079517496 schema:CreativeWork
177 https://app.dimensions.ai/details/publication/pub.1080482003 schema:CreativeWork
178 https://app.dimensions.ai/details/publication/pub.1081608880 schema:CreativeWork
179 https://app.dimensions.ai/details/publication/pub.1081900341 schema:CreativeWork
180 https://app.dimensions.ai/details/publication/pub.1082313081 schema:CreativeWork
181 https://app.dimensions.ai/details/publication/pub.1082748058 schema:CreativeWork
182 https://app.dimensions.ai/details/publication/pub.1083118733 schema:CreativeWork
183 https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1010993764
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1022702791
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t schema:sameAs https://app.dimensions.ai/details/publication/pub.1030818360
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/1097-0142(19810601)47:11<2552::aid-cncr2820471106>3.0.co;2-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1026754802
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1002/jso.2930090509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019634024
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/0014-2964(80)90206-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026853325
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/0014-2964(80)90348-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043667003
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejm197806012982203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029504560
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1056/nejm197812142992403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024442011
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1073/pnas.75.2.980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028177544
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1200/jco.1984.2.1.28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081678326
204 rdf:type schema:CreativeWork
205 https://doi.org/10.7326/0003-4819-88-1-69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073735321
206 rdf:type schema:CreativeWork
207 https://www.grid.ac/institutes/grid.266623.5 schema:alternateName University of Louisville
208 schema:name Department of Biochemistry, University of Louisville, Louisville, Kentucky, USA
209 Department of Surgery, University of Louisville, Louisville, Kentucky, USA
210 Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA
211 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...